Murdo Gordon - Amgen President
| AMGN Stock | MXN 5,779 94.00 1.65% |
President
Mr. Murdo Gordon is appointed as Executive Vice President of Global Commercial Operations of the company effective as of September 3, 2018. He will assume Hoopers role, was BristolMyers Squibbs Chief Commercial Officer since June 2016. In this role he was responsible for commercial strategy across the globe, including all sales and marketing activities, as well as customer operations, access and pricing. Prior to his current role, Gordon served as head of worldwide markets with responsibility for the promotion of all the companys brands globally. He moved to the U.S. in 2003 where he held senior commercial leadership positions in cardiovascular, neuroscience, oncology and immunology, as well as access and government affairs all areas of continuing focus and importance for Amgen. Gordon joined BristolMyers Squibb in 1989 in Canada, after receiving a BS in Cell and Molecular Biology from Concordia University, Montreal. In addition, he participated in the General Management Program, CEDEP at INSEAD, Fontainebleau, France. since 2018.
| Age | 56 |
| Tenure | 6 years |
| Phone | 805 447 1000 |
| Web | https://www.amgen.com |
Amgen Management Efficiency
The company has return on total asset (ROA) of 0.0997 % which means that it generated a profit of $0.0997 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 1.2647 %, meaning that it generated $1.2647 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Sanjiv Yajnik | Capital One Financial | 66 | |
| Michael Wassmer | Capital One Financial | 53 | |
| Wayne West | Delta Air Lines | 58 | |
| Peter Carter | Delta Air Lines | 59 | |
| Thomas Roos | UnitedHealth Group Incorporated | 50 | |
| Joanne Smith | Delta Air Lines | 60 | |
| David Wichmann | UnitedHealth Group Incorporated | 56 | |
| Brady Connor | Verizon Communications | N/A | |
| Matthew Ellis | Verizon Communications | 52 | |
| Marianne Short | UnitedHealth Group Incorporated | 68 | |
| Hans Vestberg | Verizon Communications | 58 | |
| Steven Sear | Delta Air Lines | 53 | |
| Paul Jacobson | Delta Air Lines | 47 | |
| Rahul Samant | Delta Air Lines | 56 | |
| John Rex | UnitedHealth Group Incorporated | 61 | |
| James Clark | CVS Health | 58 | |
Management Performance
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 |
Amgen Inc Leadership Team
Elected by the shareholders, the Amgen's board of directors comprises two types of representatives: Amgen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amgen. The board's role is to monitor Amgen's management team and ensure that shareholders' interests are well served. Amgen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amgen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Linda Louie, VP Officer | ||
| Robert Bradway, Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee | ||
| Murdo Gordon, Executive Vice President of Global Commercial Operations | ||
| Peter Griffith, Ex CFO | ||
| Esteban Santos, Executive Vice President Operations | ||
| Jonathan Graham, Senior Vice President General Counsel, Secretary | ||
| Nancy Grygiel, Sr Officer | ||
| Mike Zahigian, VP Officer | ||
| David MD, Ex RD | ||
| Arvind Sood, IR Contact Officer |
Amgen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amgen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.26 | |||
| Return On Asset | 0.0997 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 3.36 T | |||
| Shares Outstanding | 533.98 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.38 % | |||
| Price To Earning | 267.53 X | |||
| Price To Book | 40.33 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Amgen Stock Analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.